MISSISSAUGA, ON, Oct. 25 /CNW/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a
leader in the research and commercial development of technologies targeting
the chronic inflammation underlying cardiovascular and neurological disease,
announced that previously reported results from the ACCLAIM trial of its
Celacade(TM) technology in chronic heart failure were presented today at the
late breaking clinical trial session of the 2006 Canadian Cardiovascular
Congress being held in Vancouver. The Canadian Cardiovascular Congress is the
largest gathering of cardiovascular professionals in Canada and is designed to
showcase the best research and to promote learning through scientific
sessions, interactive workshops, and late-breaking clinical trials. The
ACCLAIM results were presented by Jean Rouleau, M.D., Principal Investigator
for the Canadian arm of the ACCLAIM trial.
